한글목차

약제 요약

Brepocitinib는 TYK2와 JAK1 이중 억제제인 퍼스트 인 클래스 TYK2와 JAK1 이중 억제제로, TYK2 또는 JAK1 단독 억제제보다 여러 염증성 자가면역질환에 대해 더 높은 효능이 예측되는 새로운 작용기전을 가지고 있습니다. 경구용 Brepocitinib은 5건의 위약 대조 임상 II상 시험을 포함해 15건의 임상 I상 및 임상 II상 시험이 완료되었으며, 5건의 위약 대조 임상 II상 시험 모두에서 통계적으로 유의미하고 임상적으로 의미 있는 유효성 결과를 도출했습니다.

주요 7 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)의 염증성근질환(IM)용 Brepocitinib에 대해 조사분석했으며, 시장 규모 예측 및 작용기서, 용법과 용량, 연구개발 활동 등의 정보를 제공하고 있습니다.

목차

제1장 리포트 서론

제2장 염증성근질환(IM)에서 Brepocitinib의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품의 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계의 새로운 치료법)

제5장 Brepocitinib 시장 평가

• 염증성근질환(IM)에서 Brepocitinib 시장 전망
• 주요 7 시장의 분석
  • 주요 7 시장의 염증성근질환(IM)용 Brepocitinib 시장 규모
• 시장의 분석 : 국가별
  • 미국의 염증성근질환(IM)용 Brepocitinib 시장 규모
  • 독일의 염증성근질환(IM)용 Brepocitinib 시장 규모
  • 영국의 염증성근질환(IM)용 Brepocitinib 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"Brepocitinib Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Brepocitinib for Inflammatory Myositis (IM) in the seven major markets. A detailed picture of the Brepocitinib for IM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Brepocitinib for IM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Brepocitinib market forecast analysis for IM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in IM.

Drug Summary:

Brepocitinib is a potential first-in-class dual inhibitor of TYK2 and JAK1, a novel mechanism of action expected to potentially provide greater efficacy in multiple highly inflammatory autoimmune diseases than agents that inhibit either TYK2 or JAK1 alone. Oral brepocitinib has been evaluated in 15 completed Phase I and Phase II studies, including five placebo-controlled Phase II studies. All five placebo-controlled Phase II studies generated statistically significant and clinically meaningful efficacy results.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Brepocitinib description, mechanism of action, dosage and administration, research and development activities in Inflammatory Myositis (IM).
• Elaborated details on Brepocitinib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Brepocitinib research and development activities in IM across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Brepocitinib.
• The report contains forecasted sales of Brepocitinib for IM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for IM.
• The report also features the SWOT analysis with analyst views for Brepocitinib in IM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Brepocitinib Analytical Perspective by DelveInsight

• In-depth Brepocitinib Market Assessment

This report provides a detailed market assessment of Brepocitinib for Inflammatory Myositis (IM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• Brepocitinib Clinical Assessment

The report provides the clinical trials information of Brepocitinib for Inflammatory Myositis (IM) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Inflammatory Myositis (IM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Brepocitinib dominance.
• Other emerging products for IM are expected to give tough market competition to Brepocitinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Brepocitinib in IM.
• Our in-depth analysis of the forecasted sales data of Brepocitinib from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Brepocitinib in IM.

Key Questions:

• What is the product type, route of administration and mechanism of action of Brepocitinib?
• What is the clinical trial status of the study related to Brepocitinib in Inflammatory Myositis (IM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Brepocitinib development?
• What are the key designations that have been granted to Brepocitinib for IM?
• What is the forecasted market scenario of Brepocitinib for IM?
• What are the forecasted sales of Brepocitinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Brepocitinib for IM?
• Which are the late-stage emerging therapies under development for the treatment of IM?

Table of Contents

1. Report Introduction

2. Brepocitinib Overview in Inflammatory Myositis (IM)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Brepocitinib Market Assessment

• 5.1. Market Outlook of Brepocitinib in Inflammatory Myositis (IM)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Brepocitinib in the 7MM for Inflammatory Myositis (IM)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Brepocitinib in the United States for Inflammatory Myositis (IM)
  • 5.3.2. Market Size of Brepocitinib in Germany for Inflammatory Myositis (IM)
  • 5.3.3. Market Size of Brepocitinib in France for Inflammatory Myositis (IM)
  • 5.3.4. Market Size of Brepocitinib in Italy for Inflammatory Myositis (IM)
  • 5.3.5. Market Size of Brepocitinib in Spain for Inflammatory Myositis (IM)
  • 5.3.6. Market Size of Brepocitinib in the United Kingdom for Inflammatory Myositis (IM)
  • 5.3.7. Market Size of Brepocitinib in Japan for Inflammatory Myositis (IM)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options